je.st
news
Tag: clinical
BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4430...
2014-12-15 18:43:01| Biotech - Topix.net
BioCryst Pharmaceuticals, Inc. today announced the dosing of the first subject in a randomized, placebo-controlled Phase 1 clinical trial to evaluate intramuscular administration of BCX4430 in healthy volunteers. BCX4430 is being developed as a potential treatment for hemorrhagic fever viruses, including Ebola virus and Marburg virus disease.
New Data Presented at ASH Annual Meeting Enhance Clinical Knowledge...
2014-12-09 06:57:07| Biotech - Topix.net
Alexion Pharmaceuticals, Inc. today announced that researchers presented data that continue to advance the understanding of atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria and provide further insight into optimal care for patients with these devastating diseases.
Tags: data
presented
knowledge
meeting
Acetylon's Selective HDAC Inhibitors To Be Featured In Multiple Presentations Of Positive Clinical And Preclinical Data At The 56th ASH Annual Meeting And Exposition
2014-12-03 06:58:10| drugdiscoveryonline News Articles
Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, recently announced that ricolinostat, the Company’s lead selective HDAC6 inhibitor, and selective HDAC1/2 inhibitors will be featured in one oral presentation and five posters at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2014, in San Francisco, CA
Tags: data
featured
multiple
positive
Science Weekly: Ebola vaccine has successful clinical trial
2014-11-30 06:30:54| Biotech - Topix.net
Researchers from the National Institutes of Health and GlaxoSmithKline , co-developers, have created a vaccine that would help prevent the Ebola virus. It is currently in the experimental phase.
Tags: science
trial
successful
weekly
CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials
2014-11-19 04:46:13| Biotech - Topix.net
CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that the Company has received notice from the United States Food and Drug Administration that its clinical trials for aldoxorubicin have been placed on partial clinical hold. All currently enrolled patients can continue receiving aldoxorubicin treatment, or comparator drugs, as per study protocols, but no new patients can be enrolled until the clinical hold is lifted.
Tags: hold
clinical
partial
affecting
Sites : [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] next »